Τίτλος:
Evaluating different strategies for poor ovarian response management: a retrospective cohort study and literature review
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
This retrospective study compares four different strategies for managing poor ovarian response (POR), namely, conventional stimulation (300 IUs) IVF–fresh embryo transfer (CONVF), mild stimulation (150 IUs) IVF–fresh embryo transfer (MILDF), mild stimulation embryo banking (MILDB), and embryo banking in natural cycles (NATB). In total, 796 POR patients were considered eligible. Statistical analysis revealed a shorter duration of stimulation and a lower required amount of gonadotropins in MILDF compared with CONVF (9.34 ± 1.17 versus 10.37 ± 1.14; 1402 ± 176 versus 3110 ± 343, P < 0.001). Comparing MILDF and MILDB, a higher number of available oocytes and embryos was observed in MILDB (2.36 ± 1.15 versus 6.58 ± 1.11; 1.72 ± 1.02 versus 3.51 ± 0.61, P < 0.001). Moreover, the MILDB presented with a lower number of required oocyte retrievals and a higher number of oocytes per oocyte retrieval compared with NATB (3.90 ± 1.56 versus 7.15 ± 1.80; 1.95 ± 0.74 versus 0.89 ± 0.20, P < 0.001). Data indicate that MILDF is equally efficient and associated with a shorter duration of stimulation and a lower required amount of gonadotropins compared with CONVF. Embryo accumulation may be more efficient compared with a fresh embryo transfer. MILDB may be a more efficient approach compared with NATB. To conclude, embryo accumulation following mild stimulation appears to form the optimal strategy for POR management. More studies are needed to verify these conclusions. © 2021 New York Academy of Sciences.
Συγγραφείς:
Pantou, A.
Giannelou, P.
Grigoriadis, S.
Maziotis, E.
Tzonis, P.
Koutsouni, A.
Pappa, C.
Philippou, A.
Koutsilieris, M.
Pantos, K.
Simopoulou, M.
Sfakianoudis, K.
Περιοδικό:
Annals of the New York Academy of Sciences
Εκδότης:
John Wiley and Sons Inc
Λέξεις-κλειδιά:
cetrorelix; choriogonadotropin alfa (drug); clomifene citrate; estradiol valerate; estradiol valerate plus norgestrel; gonadorelin antagonist; gonadotropin; recombinant follitropin; fertility promoting agent, adult; Article; cancer diagnosis; chemiluminescent microparticle immunoassay; cohort analysis; comparative study; controlled study; cryopreservation; eligibility criteria; embryo; embryo development; embryo transfer; endometrial thickness; female; female infertility; human; hydrosalpinx; informed consent; intracytoplasmic sperm injection; luteal phase; major clinical study; medical record; menstrual cycle; nonparametric test; oocyte maturation; oocyte retrieval; ovarian reserve; ovary function; pregnancy outcome; retrospective study; spontaneous abortion; statistical analysis; transvaginal echography; World Health Organization; clinical decision making; disease management; drug effect; female infertility; in vitro fertilization; meta analysis; ovary; pathophysiology; pregnancy; procedures, Clinical Decision-Making; Disease Management; Female; Fertility Agents, Female; Fertilization in Vitro; Humans; Infertility, Female; Ovarian Reserve; Ovary; Pregnancy; Pregnancy Outcome; Retrospective Studies
